If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
log(Ka) = log(K0a) + ρσ. Ka is the dissociation constant of a substituted compound, K0a is the dissociation constant when the substituent is hydrogen, ρ is a property of the unsubstituted compound and σ has a particular value for each substituent. A plot of log(Ka) against σ is a straight line with intercept log(K0a) and slope ρ. This is an example of a linear free energy relationship as log(Ka) is proportional to the standard free energy change. Hammett originally formulated the relationship with data from benzoic acid with different substituents in the ortho- and para- positions: some numerical values are in Hammett equation. This and other studies allowed substituents to be ordered according to their electron-withdrawing or electron-releasing power, and to distinguish between inductive and mesomeric effects. Alcohols do not normally behave as acids in water, but the presence of a double bond adjacent to the OH group can substantially decrease the pKa by the mechanism of keto–enol tautomerism. Ascorbic acid is an example of this effect. The diketone 2,4-pentanedione (acetylacetone) is also a weak acid because of the keto–enol equilibrium. In aromatic compounds, such as phenol, which have an OH substituent, conjugation with the aromatic ring as a whole greatly increases the stability of the deprotonated form.
Proprioception is also permanently lost in people who lose a limb or body part through injury or amputation. After the removal of a limb, people may have a confused sense of that limb's existence on their body, known as phantom limb syndrome. Phantom sensations can occur as passive proprioceptive sensations of the limb's presence, or more active sensations such as perceived movement, pressure, pain, itching, or temperature. There are a variety of theories concerning the etiology of phantom limb sensations and experience. One is the concept of "proprioceptive memory", which argues that the brain retains a memory of specific limb positions and that after amputation there is a conflict between the visual system, which actually sees that the limb is missing, and the memory system which remembers the limb as a functioning part of the body. Phantom sensations and phantom pain may also occur after the removal of body parts other than the limbs, such as after amputation of the breast, extraction of a tooth (phantom tooth pain), or removal of an eye (phantom eye syndrome). There is a decline in the sense of proprioception with ageing. This can often result in chronic lower back pain, and be the cause of falls in the elderly.
===== Surface area ===== The general trend in MOFs used for hydrogen storage is that the greater the surface area, the more hydrogen the MOF can store. High surface area materials tend to exhibit increased micropore volume and inherently low bulk density, allowing for more hydrogen adsorption to occur.
=== Rise of the independence movement === Most of the members of the former GOCA who had not died during the Ten Year's War or the Little War went into exile abroad. Instead of maintaining close connections to the new United Grand Lodge, they regularized their degrees and joined into Lodges in Mexico, Honduras, Costa Rica, the Dominican Republic, Colombia, Jamaica, Haiti, and the United States. As a diaspora, they coordinated in the creation of the Cuban Revolutionary Party and the Cuban Junta. These diaspora Masons also created new Lodges, like the Francisco Vicente Aguilera Lodge and the Ignacio Agramonte Lodge in Florida. Most of the leaders of the Cuban War of Independence were Freemasons, including José Martí, Antonio Maceo, and Máximo Gómez, but unlike during the Ten Years' War which had been directly instigated by GOCA Lodges and their leaders, a singular Freemasonic body was not directly responsible for the new Cuban Revolution. Instead, these Freemasons commingled with non-Masons and other average citizens to raise the funds, support, and armaments to fight against Spain. Because political parties had been legalized in Cuba, revolutionaries no longer needed any place to meet entirely in secret to discuss the concept of independence. The conversation was happening in the open, and throughout all of Cuba and the Caribbean. Since they were allowed to gather at the Party headquarters, political parties took the place within the ideological niche that GOCA once held.
It has been long observed that the licking of their wounds by dogs might be beneficial. Indeed, a dog's saliva is bactericidal against the bacteria Escherichia coli and Streptococcus canis, although not against coagulase-positive Staphylococcus or Pseudomonas aeruginosa. Wound licking is also important in other animals. Removal of the salivary glands of mice and rats slows wound healing, and communal licking of wounds among rodents accelerates wound healing. Communal licking is common in several primate species. In macaques, hair surrounding a wound and any dirt is removed, and the wound is licked, healing without infection. An Elizabethan collar may be used on pet animals to prevent them from biting an injury or excessively licking it, which can cause a lick granuloma. These lesions are often infected by pathogenic bacteria such as Staphylococcus intermedius. Horses that lick wounds may become infected by a stomach parasite, Habronema, a type of nematode worm. The rabies virus may be transmitted between animals, such as the kudu antelopes by wound licking of wounds with residual infectious saliva.
Sources: en.wikipedia.org
When daylight waned at mountains, an orchid-wood boat left A cloud didn't belong to this brook When maple-leaves fell last year, our fates were clear A stagnant pool of water can still sway, but you have forever gone away.
The original protein and sequence are highly conserved in evolution, and are found in humans, chimpanzees, rhesus monkeys, and bush babies. Addison's disease (typically an autoimmune destruction of the adrenal glands) may also be seen in individuals with vitiligo.
=== Historical Use of Insects in Medicine === The medicinal application of insects dates back to ancient civilizations. The Smithsonian Institution has documented historical uses of insects such as the utilization of bee venom therapy in Egyptian medicine for treating arthritis and joint pain. Ancient Greek and Roman physicians, including Galen, recorded the use of insects like cantharidin from blister beetles for dermatological conditions. In medieval Europe powdered insects were included in remedies for various ailments including infections and respiratory disorders.
Niacin is incorporated into multi-vitamin and sold as a single-ingredient dietary supplement. The latter can be immediate or slow release. Nicotinamide is used to treat niacin deficiency and for supplementation because it does not cause the flushing adverse reaction seen with nicotinic acid. Nicotinamide may be toxic to the liver at doses exceeding 3 g/day for adults. One form of dietary supplement sold in the US is inositol hexanicotinate (IHN), also called inositol nicotinate. This is inositol that has been esterified with niacin on all six of inositol's alcohol groups. IHN is usually sold as "flush-free" or "no-flush" niacin in units of 250, 500, or 1000 mg/tablets or capsules. In the US, it is sold as an over-the-counter formulation, and often is marketed and labeled as niacin, thus misleading consumers into thinking they are getting an active form of the medication. While this form of niacin does not cause the flushing associated with the immediate-release products, there is not enough evidence to recommend IHN to treat hyperlipidemia.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.